company background image
GENO logo

Genovis AB (publ.) OM:GENO Stock Report

Last Price

SEK 26.10

Market Cap

SEK 1.7b

7D

-3.2%

1Y

-28.4%

Updated

04 Jun, 2025

Data

Company Financials +

Genovis AB (publ.)

OM:GENO Stock Report

Market Cap: SEK 1.7b

Genovis AB (publ.) (GENO) Stock Overview

Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. More details

GENO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance1/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 5.3% below our estimate of its fair value

Earnings are forecast to grow 29.88% per year

Risk Analysis

Large one-off items impacting financial results

Significant insider selling over the past 3 months


GENO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Genovis AB (publ.) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Genovis AB (publ.)
Historical stock prices
Current Share PriceSEK 26.10
52 Week HighSEK 39.85
52 Week LowSEK 17.10
Beta1.91
1 Month Change9.66%
3 Month Change10.59%
1 Year Change-28.40%
3 Year Change-53.81%
5 Year Change-17.01%
Change since IPO-75.61%

Recent News & Updates

Weak Statutory Earnings May Not Tell The Whole Story For Genovis AB (publ.) (STO:GENO)

May 05
Weak Statutory Earnings May Not Tell The Whole Story For Genovis AB (publ.) (STO:GENO)

Recent updates

Weak Statutory Earnings May Not Tell The Whole Story For Genovis AB (publ.) (STO:GENO)

May 05
Weak Statutory Earnings May Not Tell The Whole Story For Genovis AB (publ.) (STO:GENO)

Genovis AB (publ.)'s (STO:GENO) 25% Share Price Surge Not Quite Adding Up

Apr 27
Genovis AB (publ.)'s (STO:GENO) 25% Share Price Surge Not Quite Adding Up

An Intrinsic Calculation For Genovis AB (publ.) (STO:GENO) Suggests It's 32% Undervalued

Mar 27
An Intrinsic Calculation For Genovis AB (publ.) (STO:GENO) Suggests It's 32% Undervalued

Investors Appear Satisfied With Genovis AB (publ.)'s (STO:GENO) Prospects

Mar 07
Investors Appear Satisfied With Genovis AB (publ.)'s (STO:GENO) Prospects

Is It Time To Consider Buying Genovis AB (publ.) (STO:GENO)?

Feb 01
Is It Time To Consider Buying Genovis AB (publ.) (STO:GENO)?

Genovis AB (publ.)'s (STO:GENO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Sep 19
Genovis AB (publ.)'s (STO:GENO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings

Aug 28
Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings

Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts

Aug 23
Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts

The Genovis AB (publ.) (STO:GENO) Analysts Have Been Trimming Their Sales Forecasts

Aug 21
The Genovis AB (publ.) (STO:GENO) Analysts Have Been Trimming Their Sales Forecasts

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Aug 12
Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Genovis AB (publ.)'s (STO:GENO) 36% Jump Shows Its Popularity With Investors

May 31
Genovis AB (publ.)'s (STO:GENO) 36% Jump Shows Its Popularity With Investors

This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate

May 09
This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Apr 26
Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Mar 18
Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash

Feb 28
What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Feb 22
We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts

Feb 20
These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts

Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be

Feb 04
Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be

Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors

Oct 06
Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors

Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?

Jun 22
Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?

What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?

May 13
What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?

Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?

Dec 22
Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?

Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?

Nov 14
Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?

Shareholder Returns

GENOSE Life SciencesSE Market
7D-3.2%2.2%0.4%
1Y-28.4%6.1%-4.0%

Return vs Industry: GENO underperformed the Swedish Life Sciences industry which returned 6.6% over the past year.

Return vs Market: GENO underperformed the Swedish Market which returned -4.3% over the past year.

Price Volatility

Is GENO's price volatile compared to industry and market?
GENO volatility
GENO Average Weekly Movement7.6%
Life Sciences Industry Average Movement8.0%
Market Average Movement6.8%
10% most volatile stocks in SE Market13.4%
10% least volatile stocks in SE Market4.2%

Stable Share Price: GENO has not had significant price volatility in the past 3 months compared to the Swedish market.

Volatility Over Time: GENO's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199933Fredrik Olssonwww.genovis.com

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues.

Genovis AB (publ.) Fundamentals Summary

How do Genovis AB (publ.)'s earnings and revenue compare to its market cap?
GENO fundamental statistics
Market capSEK 1.71b
Earnings (TTM)SEK 23.63m
Revenue (TTM)SEK 123.87m
72.3x
P/E Ratio
13.8x
P/S Ratio

Is GENO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GENO income statement (TTM)
RevenueSEK 123.87m
Cost of RevenueSEK 15.99m
Gross ProfitSEK 107.88m
Other ExpensesSEK 84.25m
EarningsSEK 23.63m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Aug 12, 2025

Earnings per share (EPS)0.36
Gross Margin87.09%
Net Profit Margin19.08%
Debt/Equity Ratio0%

How did GENO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/04 09:53
End of Day Share Price 2025/06/04 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genovis AB (publ.) is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel AlbinDanske Bank
Simon LarssonDanske Bank
Ludvig LundgrenNordea Markets